Study Results Demonstrate Early Cardio-Renal Effects of AstraZeneca’s Farxiga

June 14, 2019

Recently presented and published study results have demonstrated the ability of AstraZeneca’s Farxiga on reducing the progression of kidney disease or renal death in type-2 diabetes.

Recently presented and published study results have demonstrated the ability of AstraZeneca’s Farxiga on reducing the progression of kidney disease or renal death in type-2 diabetes, it was announced in a June 10, 2019 press release.

The pre-specified exploratory analysis of renal data from the Phase III DECLARE-TIMI 58 trial were presented at the American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, and simultaneously published in The Lancet Diabetes & Endocrinology. The data demonstrated that Farxiga provided a 47% reduction in the relative risk of the composite renal-specific outcome of kidney function decline, end-stage renal disease, or renal death when compared with placebo.

Additionally, the treatment was found to lower the relative risk of cardio-renal composite of kidney function decline, end-stage renal disease, or renal or cardiovascular death by 24% compared to placebo.

“Heart failure and renal diseases are two of the most common and early complications experienced by people living with type-2 diabetes, and are too often overlooked,” said Elisabeth Björk, senior vice-president, head of late-stage development, cardiovascular, renal, and metabolism, biopharmaceuticals R&D, AstraZeneca in the release. “They contribute to a growing economic burden on the global healthcare system and can lead to fatal outcomes for patients. These data continue to offer clinically relevant evidence of the early cardio-renal effects of Farxiga.”

The pre-specified analysis comprised 17,160 patients with type-2 diabetes and predominantly preserved renal function, irrespective of underlying atherosclerotic cardiovascular disease.

Source: AstraZeneca